Rate My Professor Klaus Hamacher

Klaus A. Hamacher, PhD, MSEE, is the Chief Nuclear Medicine Physicist for the Department of Radiology at Columbia University Irving Medical Center and NewYork-Presbyterian Hospital. He also serves as Associate Chief of the Division of Medical Physics and Director of Quality Assurance and Compliance (Ionizing Radiation, Medical Physics) at NewYork-Presbyterian and Columbia University Irving Medical Center. As Associate Professor of Radiology (Medical Physics Affiliated Faculty) in the Department of Applied Physics and Applied Mathematics, Dr. Hamacher's background and training are in nuclear medicine physics and medical imaging physics, with expertise in quality assurance and regulatory compliance. He teaches nuclear medicine physics to radiology residents and is in charge of the nuclear medicine practicum in the medical physics program of the Department of Applied Physics and Applied Mathematics.

Dr. Hamacher's research interests encompass molecular imaging in Nuclear Medicine, PET, and Nuclear Cardiology, along with dosimetry, image processing, and diagnostic medical physics. He has made contributions through peer-reviewed publications spanning neutron physics and clinical applications. Selected works include: Kaiser H et al., 'Neutron inverse optics in layered materials' (SPIE, 1994); Summhammer J et al., 'Multiphoton exchange amplitudes observed by neutron interferometry' (Phys Rev Lett, 1995); Wagh AG et al., 'Experimental separation of geometric and dynamical phases using neutron interferometry' (Phys Rev Lett, 1997); Hamacher KA and Sgouros G, 'A schema for estimating absorbed dose to organs following the administration of radionuclides with multiple unstable daughters: A matrix approach' (Med Phys, 1999); Kolbert KS et al., 'Parametric Images of Antibody Pharmacokinetics in Bi-213-HuM195 Therapy of Leukemia' (J Nucl Med, 2001); Jurcic JG et al., 'Targeted alpha particle immunotherapy for myeloid leukemia' (Blood, 2002); Konishi S et al., 'Determination of Immunoreactive Fraction of Radiolabeled Monoclonal Antibodies: What is an Appropriate Method?' (Cancer Biother Radiopharm, 2004); Vallabhajosula S et al., 'Pharmacokinetics and Biodistribution of 111In and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen' (J Nucl Med, 2005). These efforts highlight his influence in dosimetry and radioimmunotherapy.